Aarti Pharmalabs Limited has informed the Exchange about Re-appointment of Cost Auditor & Internal Auditor for FY 2026-2027
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarti Pharmalabs reported standalone net profit of Rs 17,620.20 lakhs for FY2026, down 31.5% from Rs 25,734.88 lakhs in FY2025 despite relatively flat revenue of Rs 179,755.17 lakhs (up 1.5% YoY). Consolidated revenue declined 14% to Rs 181,944.25 lakhs due to Ganesh Polychem becoming a joint venture from April 2025, making prior period numbers non-comparable. Finance costs nearly doubled to Rs 4,690.08 lakhs, significantly impacting profitability. The Board declared a final dividend of Rs 2 per share (40% on Rs 5 face value). An exceptional item of Rs 279.49 lakhs was recorded for new labour codes provision. The Q3 FY2025-26 figures were restated due to a previously omitted forward contract fair value impact of Rs 2,972.94 lakhs, which has now been recognized. Cost Auditor Smt. Ketki D. Visariya and Internal Auditor Manish Modi & Associates were reappointed for FY2026-27.
Significant PAT decline of 31.5% YoY with near-doubling of finance costs signals margin pressure and higher debt servicing costs. The restatement of Q3 figures due to derivative accounting errors may raise concerns about internal controls. However, the unmodified audit opinion and continuation of dividend provide some comfort.